权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Animal Core

动物核心

基本信息

批准号：
10549478
负责人：
Stephen Mark Tompkins
金额：
$ 39.03万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-21 至 2028-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10549478
关键词：
2019-nCoV Animal Experimentation Animal Model Animals Antibodies Antibody Therapy B-Lymphocytes Biological Assay Cattle Communities Coronavirus Coronavirus Infections Data Disease Doctor of Philosophy Ferrets Goals Hamsters Health Housing Human Immune Immunity Immunological Models Individual Infection Merbecovirus Middle East Respiratory Syndrome Coronavirus Modeling Monoclonal Antibodies Mus National Institute of Allergy and Infectious Disease Outcome Pliability Productivity Protocols documentation RNA vaccination Research Research Personnel Research Project Grants Resources Respiratory Tract Infections Running SARS coronavirus SARS-CoV-2 variant Sampling Sarbecovirus Serum Services Testing Therapeutic Monoclonal Antibodies Therapeutic antibodies Transgenic Mice Universities Vaccination Vaccine Therapy Vaccines Variant Veterinary Medicine Viral Virus Work animal coronavirus animal resource betacoronavirus betacoronavirus vaccine college coronavirus disease coronavirus vaccination coronavirus vaccine effectiveness evaluation efficacy evaluation efficacy study experience high risk human disease immunological diversity imprint improved innovation lead candidate meetings neutralizing monoclonal antibodies novel novel coronavirus pathogen pre-clinical assessment prevent programs respiratory virus response seasonal coronavirus success synergism therapeutic candidate tool training opportunity transmission process universal coronavirus vaccine vaccine candidate vaccine development vaccine efficacy vaccine-induced antibodies virus resource

项目摘要

Summary/Abstract Robust animal models of coronavirus infection are required for pre-clinical assessment of candidate vaccines and therapeutic antibodies to prevent coronavirus infection and disease. The goal of the Animal Model Core is to provide a central resource of animal models and virological tools to assess the effectiveness of vaccines and antibody therapies against betacoronaviruses in multiple animal models of infection. An experienced team of investigators will utilize established hamster, mouse, and ferret models of betacoronavirus infection to determine the efficacy of candidate therapeutic monoclonal antibodies (mAbs) developed by Project 1 and vaccines developed by Project 2. Pre-immune and transmission models will be utilized to stringently test the lead candidate vaccines. The Animal Model Core will also establish novel animal infection models with SARS- CoV-2 variant viruses, and a novel ferret model of OC43 embecovirus infection. The Animal Model Core will also complete virus neutralization assays for SARS-CoV and MERS CoV for all PLUTO investigators, centralizing resources for these viruses, eliminating redundant biosafety and Select Agent approvals. The Animal Model Core will serve as an innovative resource to assess efficacy of leading vaccine and mAb candidates for the PLUTO program through the following three Specific Aims. 1) Establish and maintain animal models of sarbecovirus and merbecovirus infection. 2) Establish and maintain coronavirus pre-immune animal models. 3) Expand and improve animal models of embecovirus and sarbecovirus infection. These complementary aims will enable rigorous assessment of vaccines and mAbs developed by the PLUTO Projects and develop new animal models of betacoronavirus infection for the project and respiratory virus research community. The novel pre-immune models will also provide data and samples to improve understanding of the impact of pre-existing betacoronavirus immunity on subsequent vaccination and infection. The outcomes of the Animal Model Core will have a positive impact on the success of the PLUTO program and provide novel information and research tools for the broader research community.

摘要/摘要候选疫苗的临床前评估需要稳健的冠状病毒感染动物模型以及预防冠状病毒感染和疾病的治疗性抗体。动物模型核心的目标提供动物模型和病毒学工具的中心资源，以评估疫苗的有效性以及在多种感染动物模型中针对β冠状病毒的抗体疗法。一支经验丰富的团队的研究者将利用已建立的仓鼠、小鼠和雪貂β冠状病毒感染模型，确定项目1开发的候选治疗性单克隆抗体（mAb）的疗效，项目2开发的疫苗。免疫前和传播模型将用于严格测试主要候选疫苗。动物模型中心还将建立新的SARS动物感染模型- CoV-2变异病毒和OC 43恩贝科病毒感染的新雪貂模型。动物模型核心将还为所有PLUTO研究人员完成SARS-CoV和MERS CoV的病毒中和试验，集中这些病毒的资源，消除冗余的生物安全和选择代理批准。的动物模型核心将作为评估领先疫苗和mAb有效性的创新资源 PLUTO计划的候选人通过以下三个具体目标。1)建立和维持肉瘤病毒和梅贝科病毒感染的动物模型。2)建立和维持冠状病毒预免疫动物模型3)扩大和完善了恩贝科病毒和肉瘤病毒感染的动物模型。这些互补的目标将能够对PLUTO开发的疫苗和单克隆抗体进行严格的评估项目和开发新的动物模型的β冠状病毒感染的项目和呼吸道病毒研究社区。新的预免疫模型还将提供数据和样本，以改善了解预先存在的β冠状病毒免疫对后续疫苗接种和感染的影响。动物模型核心的结果将对PLUTO计划的成功产生积极影响并为更广泛的研究社区提供新的信息和研究工具。